← European Medicine Shortage Tracker · all medicines

Ustekinumab shortage — availability across Europe

Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.

MEDICALLY REVIEWED
Dr. Chrysoula I. Liakou MD, PhD
Internal Medicine Specialist
Cancer Immunology Researcher
Reviewed 30 July 2026 · next review due 30 January 2027

Ustekinumab currently has availability issues reported in 3 European registers: Greece, Ireland, Italy.

Shortage  ATC L04AC05 · also listed as: USTEKINUMAB · data refreshed 11 September 2026

Key facts

As of 11 September 2026, 3 of the 9 tracked registers list current availability issues for Ustekinumab, covering 6 affected product presentations. The longest-running open report was filed in Italy on 2025-10-01 and has now been open for about 11 months. Where agencies state a cause, unexpectedly high demand lead with 2 of the 5 stated-cause reports, followed by delivery delays with 1. Notably, 3 reports have already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. Momentum is current, not historical: 2 of the open reports were filed within the last 90 days. The issue spread across registers over time rather than at once: Italy reported first (2025-10-01), with Ireland following roughly 8 months later — a pattern typical of supply problems cascading between national markets. Registers in Greece, Ireland, Italy indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Ustekinumab is coded L04AC05 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.

WhereStatus & productsSinceExpected end Reason / alternativesSource
🇬🇷 GreeceLimited availability
IMULDOSA C/S.SOL.IN 130MG/26ML (5MG/ML) BT X 1 VIAL
+ 1 more products
X 26ML
2026-06-122026-08-08Ποιοτικό πρόβλημα - Συσκευασία περιεκτικότητας LENALIDOMIDE ACCORD CAP
Alternatives: Προβλήματα στην παραγωγική Εναλλακτικά άλλα σκευάσματα της ίδιας δραστικής, μορφής και
register ↗
🇮🇪 IrelandShortage
Imuldosa 130 mg Concentrate for solution for infusion EU/1/24/1872/003 A
2026-06-162026-07-31Quality issue
Alternatives: Alternative(s) available — see the national register.
register ↗
🇮🇹 ItalyShortage
IMULDOSA
+ 2 more products
PYZCHIVA
PYZCHIVA
2025-10-01Problemi produttivi
Alternatives: AIFA: equivalents with the same active substance are available.
register ↗

New register reports per month

2025-10: 12025-11: 02025-12: 02026-01: 12026-02: 02026-03: 02026-04: 02026-05: 02026-06: 42025-102026-06

Full report history (6 register entries)

Every individual register entry for Ustekinumab in the tracked sources, newest first — including resolved and discontinued reports.

Reg.ProductStatusReportedExpected endStated reason
🇬🇷 GRIMULDOSA C/S.SOL.IN 130MG/26ML (5MG/ML) BT X 1 VIALLimited availability2026-06-192026-07-20Ποιοτικό πρόβλημα - Συσκευασία περιεκτικότητας LENALIDOMIDE
🇮🇪 IEImuldosa 130 mg Concentrate for solution for infusion EU/1/24/1872/003Shortage2026-06-162026-07-31Quality issue
🇬🇷 GRX 26MLLimited availability2026-06-122026-08-08Καθυστέρηση παράδοσης περιεκτικότητας Εναλλακτικά άλλα σκευά
🇮🇹 ITIMULDOSAShortage2026-06-03Problemi produttivi
🇮🇹 ITPYZCHIVAShortage2026-01-01Elevata richiesta
🇮🇹 ITPYZCHIVAShortage2025-10-01Elevata richiesta

Frequently asked

Is Ustekinumab currently in shortage in Europe?

Yes. As of 11 September 2026, availability issues are reported in: Greece, Ireland, Italy. Availability is national — a shortage in one country does not mean it is short everywhere.

Are there alternatives to Ustekinumab?

5 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Ustekinumab availability data come from?

Directly from the official medicines-agency registers that list Ustekinumab: EOF limited-availability list (Greece), HPRA (Ireland), AIFA (Italy). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Ustekinumab — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/ustekinumab/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Ustekinumab availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/ustekinumab/">Ustekinumab shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>
Cite: “Ustekinumab: availability status across 3 European registers — European Medicine Shortage Tracker (MobiDoctor), 11 September 2026.” Link this page and the agency record. Statuses come from the linked official registers and can change daily.